- Home
- MFIN vs SCPH Comparison
MFIN vs SCPH Comparison
Compare MFIN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- SCPH
- Stock Information
- Founded
- MFIN 1995
- SCPH 2013
- Country
- MFIN United States
- SCPH United States
- Employees
- MFIN N/A
- SCPH N/A
- Industry
- MFIN Finance: Consumer Services
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- SCPH Health Care
- Exchange
- MFIN Nasdaq
- SCPH Nasdaq
- Market Cap
- MFIN 243.9M
- SCPH 299.0M
- IPO Year
- MFIN 1996
- SCPH 2017
- Fundamental
- Price
- MFIN $10.46
- SCPH $5.65
- Analyst Decision
- MFIN Strong Buy
- SCPH Buy
- Analyst Count
- MFIN 1
- SCPH 3
- Target Price
- MFIN $12.00
- SCPH $12.00
- AVG Volume (30 Days)
- MFIN 35.3K
- SCPH 2.4M
- Earning Date
- MFIN 10-28-2025
- SCPH 11-12-2025
- Dividend Yield
- MFIN 4.58%
- SCPH N/A
- EPS Growth
- MFIN N/A
- SCPH N/A
- EPS
- MFIN 1.75
- SCPH N/A
- Revenue
- MFIN $332,256,000.00
- SCPH $49,969,000.00
- Revenue This Year
- MFIN N/A
- SCPH $104.30
- Revenue Next Year
- MFIN $1.53
- SCPH $76.06
- P/E Ratio
- MFIN $5.98
- SCPH N/A
- Revenue Growth
- MFIN 16.48
- SCPH 107.79
- 52 Week Low
- MFIN $7.52
- SCPH $1.94
- 52 Week High
- MFIN $10.98
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- MFIN 50.81
- SCPH 64.51
- Support Level
- MFIN $10.33
- SCPH $4.33
- Resistance Level
- MFIN $10.64
- SCPH $5.62
- Average True Range (ATR)
- MFIN 0.23
- SCPH 0.04
- MACD
- MFIN -0.05
- SCPH -0.01
- Stochastic Oscillator
- MFIN 31.67
- SCPH 96.67
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.